TRB-071 / TRex Bio - LARVOL DELTA

TRexBio Announces Pipeline Progress, Naming TRB-071 as a CD30 Agonist for Immune-Mediated Diseases and Advancement of Lilly-Partnered TRB-051 (Businesswire) - "Preclinical data demonstrated that CD30 agonism via TRB-071 induced Treg activation and expansion, potentially enhancing immune-regulatory capacity and reducing inflammation in colitis models. In non-human primate studies, TRB-071 induced activation and expansion of Tregs with minimal effects on other immune cell populations. TRexBio believes these findings support the potential of TRB-071 as a differentiated approach to restoring immune balance. The company is currently conducting a three-month GLP toxicology study of TRB-071 in cynomolgus monkeys....TRexBio also announced that its collaboration partner Lilly intends to initiate a Phase 2a clinical trial of TRB-051 in lupus with cutaneous involvement in the second half of 2026."

New P2a trial • Preclinical • Cutaneous Lupus Erythematosus • Immunology

TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development (Businesswire) - "Proceeds from the financing will be used to advance TRexBio’s lead candidate, TRB-061, a purpose-engineered TNFR2 agonist, through early clinical proof of concept in patients with immune mediated diseases including atopic dermatitis and ulcerative colitis....TRexBio expects to initiate a Phase 1 clinical trial with TRB-061 in the first half of 2025. The funding will also support the expansion of TRexBio’s pipeline, including early development of therapeutic candidate TRB-071."

Financing • New P1 trial • Pipeline update • Atopic Dermatitis • Ulcerative Colitis